Top Highlights From the 2015 AACR Annual Meeting

Slideshow

This slide show features some of the top highlights from the 2015 American Association for Cancer Research (AACR) Annual Meeting.

REFERENCES1. Jameson GS, Borazanci E, Poplin E, et al. High complete and partial response rate in a phase Ib pilot trial with cisplatin plus albumin-bound paclitaxel and gemcitabine in patients with advanced pancreatic cancer. Presented at the American Association for Cancer Research Annual Meeting; April 18-22, 2015; Philadelphia. Abstract LB-003.2. Ribas A, Schachter J, Long GV, et al. Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma. Presented at the American Association for Cancer Research Annual Meeting; April 18-22, 2015; Philadelphia. Abstract CT101.3. Hodi FS, Postow MA, Chesney J, et al. Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone. Presented at the American Association for Cancer Research Annual Meeting; April 18-22, 2015; Philadelphia. Abstract 2860.4. Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Presented at the American Association for Cancer Research Annual Meeting; April 18-22, 2015; Philadelphia. Abstract 2859.5. Mateo J, Sandhu S, Miranda S, et al. DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer. Presented at the American Association for Cancer Research Annual Meeting; April 18-22, 2015; Philadelphia. Abstract CT322.6. Beachler DC, Kreimer AR, Schiffman M, et al. Efficacy of the HPV16/18 vaccine against cervical, anal, and oral HPV infection among women with and without previous HPV16/18 exposure. Presented at the American Association for Cancer Research Annual Meeting; April 18-22, 2015; Philadelphia. Abstract 4680.

Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content